Bayer Will Invest €4 Million in its Plant in La Felguera, Asturias

Bayer is committed to Spain. Bayer’s plant in La Felguera (Asturias) celebrates its eightieth anniversary and has done so by announcing an investment of €4 million for this year, with the aim of further developing digitalization, increasing efficiency, and production flexibility of the Asturian facilities.

The center, a global benchmark for producing the active ingredient in Aspirin for the whole world, was attended by the President of the Principality of Asturias, Adrián Barbón, as well as the CEO of Bayer in Spain, Bernardo Kanahuati, and other personalities.

During the institutional ceremony held this Monday, the CEO of Bayer in Spain and Portugal indicated that the La Felguera plant is a world reference, participating in strategic projects of great importance. He recalled that in the last five years, €27 million have been invested, to which the 4 million for this year must be added.

The La Felguera plant currently has a staff of one hundred people, which rises to 150 workers if the personnel of the external companies is added. When asked about the impact of inflation on the production process, the plant manager indicated that it is limited because the energy costs, although they do affect the plant, it is not a high consumption plant like other industries.

Read more about Bayer and find the most important financial news of the day with our companion app Born2Invest.

Bayer has invested €27 million in the last five years in the La Felguera center

Since its opening in 1942, and throughout its eighty years of history, the La Felguera plant has become a world reference for the production of acetylsalicylic acid, the active component of Aspirin and Adiro. This component, in powder form, is exported from Asturias to eight Bayer production centers around the world where it is compressed into tablets according to its different presentations (tablets, effervescent, chewable, granulated) and distributed to all the markets in which the company operates.

In addition to the active ingredient Aspirin, the Asturian plant also produces other active substances and products such as Canestén (crotimazol), antifungal treatment for treating fungal infections, or, from November 2021, Nifedipine, a product indicated for the treatment of angina pectoris.

Bayer posted a profit of €2.99 billion in the first half of 2022, compared with a loss of €246 million in the first half of last year. The company’s first-half revenue came in at €27.46 billion, up 18.4% year-on-year in 2021, while the pharmaceuticals business posted a 6.6% rise in sales to €9.44 billion. Meanwhile, the over-the-counter drugs business posted an 18.3% increase in sales, up to €3.08 billion.

__

(Featured image by qimono via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.